PeptidePedia The community reference

Special:RecentChanges

Change log·7,183 revisions·page 10 of 72

Every change to PeptidePedia Wiki, newest first. N marks a new page, m a minor edit and b an edit by an approved bot. The byte figure is the page size after the edit; the coloured figure is the change. 7,183 changes are logged in total.

7,183Logged changes
598Bot edits
175Page creations
256Active editors

6 May 2026

  1. (diff | hist) 14:15 Talk:Glucagon 611 +237 MolarMassMaeve (talk | contribs) /* Energy-expenditure figure */ reply
  2. (diff | hist) 14:10 Talk:SURMOUNT trial programme 748 +149 TirzTaxonomist (talk | contribs) /* Tolerability at larger effect */ reply
  3. (diff | hist) 13:55 Talk:Personal importation policy 748 +67 NPOV_Nadia (talk | contribs) /* Community reports as evidence */ reply
  4. (diff | hist) 13:48 Talk:Trial data comparison 611 +105 ITT_Imelda (talk | contribs) /* Cross-trial tabulation and the estimand problem */ reply
  5. (diff | hist) 13:05 Talk:Preparative HPLC purification 748 +180 CrudePeptidePearl (talk | contribs) /* Cost of purity */ reply
  6. (diff | hist) 10:40 Talk:Glucagon 400 +200 PlainNumbersPip (talk | contribs) /* Energy-expenditure figure */ new section
  7. (diff | hist) 10:35 Talk:SURMOUNT trial programme 537 +180 ToleranceTove (talk | contribs) /* Tolerability at larger effect */ new section
  8. (diff | hist) 10:22 Talk:Trial data comparison 400 +461 ForestPlotFinn (talk | contribs) /* Cross-trial tabulation and the estimand problem */ new section
  9. (diff | hist) 10:20 Talk:Personal importation policy 537 +129 ImportRecordIna (talk | contribs) /* Community reports as evidence */ new section
  10. (diff | hist) 09:53 Glucagon 7,074 ±0 EmptyingElke (talk | contribs) split §Pharmacology into receptor binding and downstream signalling [rollback]
  11. (diff | hist) 09:30 Talk:Preparative HPLC purification 537 +156 CDMO_Caradoc (talk | contribs) /* Cost of purity */ new section
  12. (diff | hist) 05:33 WuXi TIDES 16,434 ±0 NNT_Nerys (talk | contribs) label the reception tally as weak, self-selected evidence at this point of use [rollback]

5 May 2026

  1. (diff | hist) 20:02 Research use only 7,990 ±0 StateBoardStace (talk | contribs) add the note that this wiki does not give legal advice [rollback]
  2. (diff | hist) m 02:52 Temperature excursion 24,964 ±0 GMP_Gita (talk | contribs) add the customs-detention point as a logistics fact, sourced [rollback]

4 May 2026

  1. (diff | hist) m 22:44 Retention time 4,104 ±0 FormularyFrida (talk | contribs) add the equilibration time to the gradient description [rollback]
  2. (diff | hist) 21:43 Lixisenatide 4,195 ±0 INN_Ingrid (talk | contribs) attribute the mechanism claim to the review rather than stating it flatly [rollback]
  3. (diff | hist) m 21:17 Global access disparity 4,391 ±0 TitrationTheo (talk | contribs) state that the pricing data is self-reported where it is [rollback]
  4. (diff | hist) 20:41 Trial data comparison 7,303 ±0 ArchiveAudit (talk | contribs) add a second default preset at a common vial strength [rollback]
  5. (diff | hist) m 18:28 Electrospray ionisation 4,323 ±0 AAA_Analyst (talk | contribs) give the limit of quantitation with the signal-to-noise ratio it assumes [rollback]
  6. (diff | hist) m 17:08 Liquid chromatography-mass spectrometry 4,463 ±0 ApoB_Aurelio (talk | contribs) close an unbalanced quotation mark [rollback]
  7. (diff | hist) 13:55 Talk:Glossary of peptide terminology 748 +86 GlossaryGleb (talk | contribs) /* Completeness */ reply
  8. (diff | hist) 13:50 Talk:Number needed to treat 748 +87 NNT_Nerys (talk | contribs) /* Incommensurable outcomes */ reply
  9. (diff | hist) 12:55 Talk:Batch number 748 +108 BatchNumberBede (talk | contribs) /* Inferring volume from sequence numbers */ reply
  10. (diff | hist) 10:42 Shenzhen Hybio Pharmaceutical 17,716 ±0 DiagramDelphine (talk | contribs) add the incorporation year, attributed to the registry record [rollback]
  11. (diff | hist) 10:20 Talk:Glossary of peptide terminology 537 +144 ManualOfStyleMo (talk | contribs) /* Completeness */ new section
  12. (diff | hist) 10:15 Talk:Number needed to treat 537 +210 BalanceBirdie (talk | contribs) /* Incommensurable outcomes */ new section
  13. (diff | hist) 09:35 Talk:Batch number 537 +179 LedgerLysander (talk | contribs) /* Inferring volume from sequence numbers */ new section
  14. (diff | hist) 03:21 Lyophilisation 28,679 ±0 SelectTrialSam (talk | contribs) add short description [rollback]
  15. (diff | hist) m 01:38 Prior authorisation 4,216 ±0 DisparityDagny (talk | contribs) clarify that a discontinued shortage listing changed the compounding position [rollback]

3 May 2026

  1. (diff | hist) 21:19 GenScript Peptides 17,833 ±0 VerifyVesna (talk | contribs) add the storage and handling guidance the organisation publishes [rollback]
  2. (diff | hist) m 15:43 Shanghai Sigma-Audley New Material Technology 15,579 ±0 AxisLabelAgda (talk | contribs) British spelling per PP:MOS [rollback]
  3. (diff | hist) 15:27 Beyond-use date 23,171 ±0 LyophilLena (talk | contribs) give the concentration in mg/mL as well as in units [rollback]
  4. (diff | hist) 14:12 Active pharmaceutical ingredient 4,569 ±0 SafetySignalSid (talk | contribs) add the pharmacopoeial chapter reference [rollback]
  5. (diff | hist) m 13:49 Flourishglobal Peptide Biotech 14,771 ±0 ReportReaderRilla (talk | contribs) rm the adjective — an organisation article describes, it does not praise [rollback]
  6. (diff | hist) 09:20 Talk:Orforglipron 822 +98 OrforglipronOona (talk | contribs) /* Cross-trial comparison in the last section */ reply
  7. (diff | hist) m 09:12 Solid-phase peptide synthesis 5,359 ±0 CouplingCillian (talk | contribs) rm a duplicated category [rollback]
  8. (diff | hist) 08:52 Timeline of incretin therapeutics 4,460 ±0 Retention_Time_Rae (talk | contribs) attribute the mechanism claim to the review rather than stating it flatly [rollback]
  9. (diff | hist) 01:06 Cold chain 27,220 ±0 BlindSampleBrid (talk | contribs) rm the shipping recommendation — that is advice, not description [rollback]

2 May 2026

  1. (diff | hist) 22:10 GL Biochem (Shanghai) 16,491 ±0 TirzTaxonomist (talk | contribs) add the lead time for catalogue lines, as reported [rollback]
  2. (diff | hist) 18:49 Missed dose 5,277 ±0 SelectTrialSam (talk | contribs) correct the unit conversion — U-100 not U-40 [rollback]
  3. (diff | hist) 14:20 Talk:Residual solvent 748 +91 Chromatokid (talk | contribs) /* TFA: solvent or counterion? */ reply
  4. (diff | hist) 14:03 Talk:Incretin effect 822 +275 PlainNumbersPip (talk | contribs) /* Percentage calculation — should the formula be explained further? */ reply
  5. (diff | hist) 13:35 Talk:Orforglipron 611 +228 ForestPlotFinn (talk | contribs) /* Cross-trial comparison in the last section */ reply
  6. (diff | hist) m 11:52 Peptide aggregation 5,516 ±0 TechnicianTeal (talk | contribs) convert a hard-coded date to the house format [rollback]
  7. (diff | hist) 11:42 Talk:Incretin effect 611 +239 Peptide_Pete (talk | contribs) /* Percentage calculation — should the formula be explained further? */ reply
  8. (diff | hist) 10:50 Talk:Residual solvent 537 +210 TFA_Counterion (talk | contribs) /* TFA: solvent or counterion? */ new section
  9. (diff | hist) 10:10 Talk:Orforglipron 400 +151 OrforglipronOona (talk | contribs) /* Cross-trial comparison in the last section */ new section
  10. (diff | hist) 09:15 Talk:Incretin effect 400 +213 PlainNumbersPip (talk | contribs) /* Percentage calculation — should the formula be explained further? */ new section
  11. (diff | hist) 06:07 Cost per milligram 4,125 ±0 PriorAuthPaz (talk | contribs) rm the advice on how to obtain coverage [rollback]
  12. (diff | hist) 03:50 Chain of custody 5,157 ±0 GroupBuyGalen (talk | contribs) serial comma per PP:MOS [rollback]
  13. (diff | hist) 00:53 Intention-to-treat analysis 4,963 ±0 EndpointEnid (talk | contribs) state the non-inferiority margin, since the design was non-inferiority [rollback]
  14. (diff | hist) m 00:29 Enteroendocrine L cell 5,083 ±0 ArcuateArt (talk | contribs) add a figure for the secretion time course and caption it [rollback]

1 May 2026

  1. (diff | hist) m b 17:24 MOTS-c 4,670 ±0 StubSorterBot (talk | contribs) bot: normalise citation format [rollback]
  2. (diff | hist) 15:43 Resin cleavage 4,310 ±0 ColdChainCleo (talk | contribs) fix hyphenation per PP:MOS [rollback]
  3. (diff | hist) 14:05 Talk:Missed dose 748 +104 TitrationTheo (talk | contribs) /* Doubling a dose */ reply
  4. (diff | hist) 10:20 Talk:Missed dose 537 +147 SafetySignalSid (talk | contribs) /* Doubling a dose */ new section
  5. (diff | hist) m b 08:30 Peptide stability table 6,886 ±0 CategoryBot (talk | contribs) bot: normalise citation format [rollback]
  6. (diff | hist) 03:49 Qingdao Saber Technology Pharmaceutical 14,592 ±0 NavboxNiko (talk | contribs) add the outbound storefront link, marked nofollow and sponsored per the external-links convention [rollback]

30 April 2026

  1. (diff | hist) 23:07 Adverse effects of GLP-1 receptor agonists 5,791 ±0 BiliaryBea (talk | contribs) ce per PP:MOS [rollback]
  2. (diff | hist) m 22:49 GLP-1 receptor agonist 11,264 ±0 ForestPlotFinn (talk | contribs) expand §Material obtained outside licensed supply [rollback]
  3. (diff | hist) 14:58 Talk:Liraglutide 748 +153 MolarMassMaeve (talk | contribs) /* Heptamer self-association */ reply
  4. (diff | hist) m b 14:09 Amylin 5,795 ±0 CategoryBot (talk | contribs) bot: normalise citation format [rollback]
  5. (diff | hist) 13:50 Talk:HOMA-IR 748 +97 PlainNumbersPip (talk | contribs) /* Population versus individual */ reply
  6. (diff | hist) 13:25 Talk:Deamidation 748 +129 StabilityStig (talk | contribs) /* Storage versus manufacture */ reply
  7. (diff | hist) 11:44 Talk:Liraglutide 537 +169 StabilityStig (talk | contribs) /* Heptamer self-association */ new section
  8. (diff | hist) 10:26 Talk:Vial 1,581 +65 Ref_Desk_Ron (talk | contribs) /* Should the excess-volume table be here or at Underfilling? */ reply
  9. (diff | hist) 10:15 Talk:HOMA-IR 537 +180 ForestPlotFinn (talk | contribs) /* Population versus individual */ new section
  10. (diff | hist) 09:50 Talk:Deamidation 537 +190 ChainCustodyChad (talk | contribs) /* Storage versus manufacture */ new section
  11. (diff | hist) m 07:33 Nantong Guangyuan Chemical 15,114 ±0 PrimarySrcPatia (talk | contribs) add the lead time for catalogue lines, as reported [rollback]
  12. (diff | hist) 02:14 Retatrutide 7,421 ±0 MolarMassMaeve (talk | contribs) give the INN alongside the trade name at first mention [rollback]

29 April 2026

  1. (diff | hist) m 16:05 Mass spectrometry 5,612 ±0 MissedDoseMik (talk | contribs) give the injection volume, without which the loading cannot be judged [rollback]
  2. (diff | hist) 13:10 Talk:Mass spectrometry 748 +148 FmocFrancis (talk | contribs) /* Stereochemistry gap */ reply
  3. (diff | hist) 12:17 Contract development and manufacturing organisation 5,011 ±0 DiagramDelphine (talk | contribs) consistent en dashes in ranges [rollback]
  4. (diff | hist) 09:35 Talk:Mass spectrometry 537 +161 AAA_Analyst (talk | contribs) /* Stereochemistry gap */ new section
  5. (diff | hist) 05:48 Glossary of peptide terminology 4,744 ±0 PortalPolly (talk | contribs) de-duplicate a repeated sentence [rollback]

28 April 2026

  1. (diff | hist) 14:00 Talk:Peptide synthesis 748 +129 Areapercent_Ayo (talk | contribs) /* Impurity profile as a signature */ reply
  2. (diff | hist) 13:11 Shanghai ERP Biotechnology 14,637 ±0 COA_Colwyn (talk | contribs) add the standing talk-page note link to the banner [rollback]
  3. (diff | hist) 10:25 Talk:Peptide synthesis 537 +160 Chromatokid (talk | contribs) /* Impurity profile as a signature */ new section
  4. (diff | hist) 09:47 Talk:Vial 1,370 +132 SeeAlsoSelma (talk | contribs) /* Should the excess-volume table be here or at Underfilling? */ reply
  5. (diff | hist) m 05:48 Deamidation 5,263 ±0 IsocraticIla (talk | contribs) rm the assertion that two laboratories must agree; they need not [rollback]

27 April 2026

  1. (diff | hist) 23:35 Dulaglutide 5,490 ±0 BUD_Bertram (talk | contribs) fix the amino-acid substitution — position 8, not position 2 [rollback]
  2. (diff | hist) 16:02 Talk:Vial 1,159 +407 UnderfillUna (talk | contribs) /* Should the excess-volume table be here or at Underfilling? */ reply
  3. (diff | hist) m 15:03 Haemoglobin A1c 4,243 ±0 FirstEditFabian (talk | contribs) state whether the figure is a mean or a median [rollback]
  4. (diff | hist) 15:00 PolyPeptide Group (Hangzhou) 18,363 ±0 BlindSampleBrid (talk | contribs) attribute the documentation description to the purchaser reports it comes from [rollback]
  5. (diff | hist) 14:05 Talk:Lot traceability 748 +131 VerifyVesna (talk | contribs) /* Observable consequences framing */ reply
  6. (diff | hist) 13:55 Talk:Intention-to-treat analysis 748 +60 CrossRefCleve (talk | contribs) /* Which estimand a source used */ reply
  7. (diff | hist) 13:19 Talk:Vial 948 +226 CrossRefCleve (talk | contribs) /* Should the excess-volume table be here or at Underfilling? */ new section
  8. (diff | hist) m 13:04 Tianjin Finder Chemical 14,449 ±0 SubQ_Solveig (talk | contribs) state the city and province of the registered address [rollback]
  9. (diff | hist) 12:36 Gastric emptying 5,565 ±0 DataTableDunja (talk | contribs) add the enteroendocrine cell type responsible for secretion [rollback]
  10. (diff | hist) 10:30 Talk:Lot traceability 537 +211 DisclosureDido (talk | contribs) /* Observable consequences framing */ new section
  11. (diff | hist) 10:20 Talk:Intention-to-treat analysis 537 +146 DataTableDunja (talk | contribs) /* Which estimand a source used */ new section
  12. (diff | hist) 04:52 Proglucagon 6,709 ±0 HalfLifeHavel (talk | contribs) expand §Tissue-specific processing [rollback]
  13. (diff | hist) 04:27 Trifluoroacetate counterion 5,116 ±0 Retention_Time_Rae (talk | contribs) add the cross-link to the compendial chapter [rollback]
  14. (diff | hist) 03:09 Grey market 4,279 ±0 CDMO_Caradoc (talk | contribs) add the figure for the lyophilisation cycle and caption it [rollback]

26 April 2026

  1. (diff | hist) m 20:41 Insulin syringe 4,944 ±0 UnitAuditUwe (talk | contribs) convert the conversion list to a table so the three syringe scales align [rollback]
  2. (diff | hist) m 19:28 SUSTAIN trial programme 5,153 ±0 NNT_Nerys (talk | contribs) correct the baseline mean — transposed digits [rollback]
  3. (diff | hist) 15:56 Underfilling 4,882 ±0 EndotoxinEd (talk | contribs) add the citation for the blind-sampling discussion [rollback]
  4. (diff | hist) 14:00 Talk:Triple agonist 748 +74 EscalationEira (talk | contribs) /* Predicted failure mode */ reply
  5. (diff | hist) 13:15 Talk:Exenatide 885 +179 ClinicCorrespondent (talk | contribs) /* Microsphere nodules */ reply
  6. (diff | hist) m 12:53 Medutest 5,018 ±0 CouplingCillian (talk | contribs) expand §What a submitted report establishes [rollback]